Valuation: AstraZeneca PLC

Market Cap 290B 260B 239B 217B 405B 27,543B 413B 2,847B 1,144B 14,484B 1,089B 1,065B 45,692B P/E 2026 *
24.5x
P/E 2027 * 20.9x
Enterprise Value 309B 277B 255B 231B 432B 29,370B 440B 3,035B 1,220B 15,445B 1,161B 1,136B 48,724B EV / Sales 2026 *
4.89x
EV / Sales 2027 * 4.5x
Free-Float
96.62%
Yield 2026 *
1.77%
Yield 2027 * 1.9%
1 day+6.96%
1 week+8.86%
Current month+13.68%
1 month+13.68%
3 months+9.75%
6 months+0.09%
Current year+1.23%
1 week 12,642
Extreme 12642
14,002
1 month 11,716
Extreme 11716
14,002
Current year 10,524
Extreme 10524
15,732
1 year 10,524
Extreme 10524
15,732
3 years 9,461
Extreme 9461
15,732
5 years 8,090.32
Extreme 8090.32
15,732
10 years 3,996
Extreme 3996
15,732
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Free

See remarks

2 0.0000% -
9/14/26 Free

Chief Financial Officer

73 0.0000%
9/14/26 Buy

Chairman

2,500 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+6.96%+8.86% - - 290B
Average +6.96%
Weighted average by Cap. +6.96%

Financials

2026 *2027 *
Net sales 63.3B 56.74B 52.22B 47.27B 88.45B 6,010B 90.04B 621B 250B 3,161B 238B 232B 9,971B 67.38B 60.4B 55.59B 50.32B 94.16B 6,398B 95.85B 661B 266B 3,365B 253B 247B 10,614B
Net income 11.75B 10.53B 9.69B 8.77B 16.42B 1,115B 16.71B 115B 46.33B 587B 44.09B 43.15B 1,851B 13.69B 12.27B 11.29B 10.22B 19.12B 1,299B 19.47B 134B 53.97B 683B 51.36B 50.26B 2,156B
Net Debt 19.25B 17.25B 15.88B 14.37B 26.9B 1,828B 27.38B 189B 75.9B 961B 72.23B 70.69B 3,032B 13.28B 11.9B 10.95B 9.92B 18.55B 1,261B 18.89B 130B 52.36B 663B 49.83B 48.77B 2,092B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-30 GBX 13,960.00 +6.96% 4,486,055
26-10-29 GBX 13,052.00 +2.26% 1,421,354
26-10-28 GBX 12,764.00 -0.45% 1,182,725
26-10-27 GBX 12,822.00 -0.25% 2,232,524
26-10-26 GBX 12,854.00 +0.23% 1,613,010
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
187.02USD
Average target price
210.53USD
Spread / Average Target
+12.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC